Zhitong Finance App News, Baihua Pharmaceutical (600721.SH) issued a stock trading risk warning notice stating that the company is a CRO enterprise that mainly develops small-molecule chemical generic drugs. Its main business is to provide customers with a “one-stop” full-process service for drug development and registration, mainly small-molecule generic drugs. Most of the main R&D projects come from customers entrusting and setting up projects independently by the company, and do not involve innovative drug research and development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.